The leading source for credible citizen reporting

Report Your News
Take the tour...

This event is older than two months and is no longer active. Some links older than two months could be broken.

Report Your News

Click here to post a new related report

Dendreon Struts Its Stuff

Source: The Motley Fool
Newark : NJ : USA | 2 months ago  
Views: 1
The biotech company now expects to submit the updated marketing application for its prostate cancer vaccine, Provenge, to the Food and Drug Administration by mid-November. That would put an approval around May of next year, assuming the FDA gives it a six-month review.
  • Print
  • Share:
  • Share
  • Digg
  • Reddit
  • Facebook
  • Stumbleupon

Related Allvoices Contributions

News Stories
 
  • News Source: The Motley Fool | 2 months ago
    With the market rally wearing thin as the economy bottoms out, it feels as if Mr. Market's bartender shouted "last call" and folks are hooking up as if this were the last night of spring break.  Getting in the way of all of the real mergers are the...
  • News Source: The Motley Fool | 2 months ago
    Analysts see the company earning $0.26 a share in its latest quarter, well short of the $0.47 a share it rang up a year ago. Tuesday, providing investors with the opportunity to take the pulse of several different industries...The athletic footwear...
  • News Source: The Motley Fool | 2 months ago
    This morning, the company announced positive results in testing its cancer drug Campath in patients with chronic lymphocytic leukemia (CLL). The drug is already approved to treat CLL as a monotherapy, but Genzyme is trying to expand its label to...
  • News Source: The Motley Fool | 2 months ago
    The biotech company now expects to submit the updated marketing application for its prostate cancer vaccine, Provenge, to the Food and Drug Administration by mid-November. That would put an approval around May of next year, assuming the FDA gives it...
Most Popular Reports

Related Allvoices Reports

Contributions

Help and Accounts


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2009. All rights reserved.